Ventricular Assist Device - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, ventricular assist devices market size in 2026 is estimated at USD 1.88 billion, growing from 2025 value of USD 1.73 billion with 2031 projections showing USD 2.81 billion, growing at 8.44% CAGR over 2026-2031.

This report Segments by Product Type (Left Ventricular Assist Device (LVAD), Right Ventricular Assist Device (RVAD) and More), Design (Implantable VAD, Transcutaneous/External VAD and More), Application/ Therapy (Bridge-To-Transplant (BTT), Destination Therapy, and More), and Geography (North America, Europe and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Ventricular Assist Device Market Trends and Insights

Growing burden of cardiac diseases & heart failure

Heart-failure prevalence rose to 6.7 million Americans in 2025 and will climb to 11.4 million by 2050, widening the patient base for mechanical support. Younger cohorts and racial minorities are showing steeper incidence curves, which shifts device demand toward patients likely to need decades of circulatory assistance. Estimates place the cumulative cost of heart failure at USD 420 billion by mid-century, encouraging payers to support durable devices over repeated hospitalizations.

Technological advances

Magnetic levitation pumps such as HeartMate 3 post 63.3% five-year survival and lower thrombosis risk than earlier bearings-based systems. Miniaturised percutaneous pumps now use 9 Fr delivery profiles with 100% valve-crossing success in more than 500 procedures. Early studies on wireless power transfer demonstrate safe energy delivery across seven meters, pointing to future cable-free, fully implantable platforms.

High device and procedure costs

Implantation averages USD 175,420 and total stay costs approach USD 193,192, with a further USD 52,068 for readmissions, frustrating adoption in cost-sensitive markets. Limited insurer coverage and large capital budgets deter smaller centres, even as cost-effectiveness improves with battery longevity and reduced complication rates.

Other drivers and restraints analyzed in the detailed report include:

1. Expanding destination therapy amid organ donor shortage
2. Ageing population and healthcare spending
3. Device-related complications and recalls

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Left Ventricular Assist Devices command 72.65% of 2025 revenues, the largest slice of the Ventricular Assist Devices market. Their 9.08% CAGR to 2031 reflects broad clinical eligibility and strong data on long-term survival. The Ventricular Assist Devices market size for LVADs is forecast to expand steadily as magnetic levitation platforms reduce thrombosis and pump stoppage rates. LVAD innovation now centres on wireless power and miniature control units, features that will narrow the gap with total artificial hearts.

Right Ventricular Assist Devices fill niche needs in isolated right-side failure, and Biventricular systems address complex bi-ventricle dysfunction, while total artificial hearts such as Aeson progress in pilot roll-outs. Clinical evidence highlights a 14-year support record for a single LVAD recipient, underscoring the destination-therapy potential of new models.

Geography Analysis

North America holds 42.10% of 2025 sales, reflecting robust Medicare coverage, centre-of-excellence networks, and a rich innovation pipeline. Registry data and outcome transparency continue to boost clinician confidence. The region is the primary launch ground for new platforms granted FDA breakthrough designation, enhancing first-mover revenues.

Europe presents steady uptake, leveraging harmonised regulatory frameworks and established heart-failure networks. Adoption is tempered by slower reimbursement updates and occasional device lag, yet the region is home to landmark innovations like the Aeson total artificial heart and strong academic-industry partnerships.

Asia-Pacific is the fastest growing at a 10.43% CAGR. Urbanising economies and rising cardiovascular risk deepen unmet need, while policy reforms widen device reimbursement. However, limited trained personnel and cost constraints slow penetration in secondary cities, making training programmes and public-private financing critical.

1. Abbott Laboratories
2. Medtronic
3. Johnson and Johnson (Abiomed)
4. Berlin Heart
5. SynCardia Systems
6. Jarvik Heart
7. BiVACOR
8. Calon Cardio-Technology Ltd.
9. Carmat
10. ReliantHeart Inc.
11. Evaheart Inc.
12. Supira Medical
13. CardioBridge GmbH
14. Lepu Medical
15. CH Biomedical Inc.
16. Corwave
17. Windmill Cardiovascular Systems
18. VentureMed Group
19. Sun Medical Technology Research Corp.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support